Biotechnology at OECD


Published on

Published in: Business, Economy & Finance
1 Like
  • Be the first to comment

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Biotechnology at OECD

  1. 1. Can Bioscience Underpin Economic Strategies? <ul><li>Iain Gillespie, </li></ul><ul><li>Head of Division. </li></ul>BIOTECHNOLOGY DIVISION
  2. 2. OECD and Biotechnology <ul><li>Biotechnology as a microeconomic driver for growth </li></ul><ul><li>Harmonisation of regulatory regimes and provision of positive and stable international business environment </li></ul><ul><li>Biotechnology as a driver for market transition </li></ul>BIOTECHNOLOGY DIVISION
  3. 3. Which Economic Strategies? <ul><li>Health </li></ul><ul><li>Sustainability (decoupling growth from environmental degradation = eco-efficiency ) </li></ul><ul><li>Nutrition/ Food Security </li></ul><ul><li>Globalisation and trade. </li></ul><ul><li>Growth </li></ul>BIOTECHNOLOGY DIVISION
  4. 4. Health <ul><li>Potential of molecular markers to add value to medicines? </li></ul><ul><li>New disease and drug targets? </li></ul><ul><li>Interoperability or Tower of Babel? </li></ul><ul><li>New business & innovation models? </li></ul>BIOTECHNOLOGY DIVISION
  5. 5. Model-adjusted Mean Change from Baseline in ADAS-cog by treatment week ITT population PGx ITT population by APOE4 status* *Excluding subjects 364, 737 and 1027 -2.0 -1.0 0.0 1.0 0 4 8 12 16 20 24 Placebo M 2mg M 4mg M 8mg Mean change in ADAS-cog score Weeks of Treatment -2.0 -1.0 0.0 1.0 2.0 0 4 8 12 16 20 24 E4-, placebo E4+, placebo E4-, M 2mg E4+, M 2mg E4-, M 4mg E4+, M 4mg E4-, M 8mg E4+, M 8mg Mean change in ADAS-cog score Weeks of Treatment
  6. 6. Linear Model <ul><li>The current approach….. </li></ul>BIOTECHNOLOGY DIVISION Discovery Development Delivery Diffusion
  7. 7. DEVELOPMENT IDENTIFICATION of NEED DIFFUSION DELIVERY <ul><li>Research </li></ul><ul><li>Policy </li></ul><ul><li>Guidelines-eg </li></ul><ul><li>human subjects, </li></ul><ul><li>consent, privacy. </li></ul><ul><li>Research </li></ul><ul><li>Ethics Boards </li></ul><ul><li>RESEARCH </li></ul><ul><li>Industry </li></ul><ul><li>Policy </li></ul><ul><li>Feasibility </li></ul><ul><li>Trials </li></ul><ul><li>Formulation </li></ul><ul><li>IPR </li></ul><ul><li>Healthcare </li></ul><ul><li>Policy </li></ul><ul><li>Accessible </li></ul><ul><li>Affordable </li></ul><ul><li>Cost-effective </li></ul><ul><li>Regulatory/ </li></ul><ul><li>Legislative </li></ul><ul><li>Policy </li></ul><ul><li>Patient safety </li></ul><ul><li>Standards </li></ul><ul><li>Medical guidelines </li></ul>Decisions Match innovation and health needs Enabling environment? Making Demand and Supply Work Together COMMERCIALISATION
  8. 8. Industrial <ul><li>Decouple growth from pollution? </li></ul><ul><li>Platform technologies/ intermediates? </li></ul><ul><li>Leverage infrastructure? </li></ul><ul><li>Will subsidies be necessary? </li></ul>BIOTECHNOLOGY DIVISION
  9. 9. Pollution (e.g., CO 2 , toxic chemicals) Economic Growth (e.g., employment, GDP) Conventional technology Sustainability via the bio based economy Eco-efficiency & renewable feedstock BIOTECHNOLOGY DIVISION
  10. 10. Renewable T-Shirts! BIOTECHNOLOGY DIVISION
  11. 11. Cargill-Dow (Nebraska) BIOTECHNOLOGY DIVISION
  12. 12. Market Potential <ul><li>Recognise opportunities to realise latent value natural processes. </li></ul><ul><li>Significant economic potential in manufacturing and processing industry (sector provides 17% direct economic value in OECD countries - big pharma another 2-3%). </li></ul><ul><li>But must avoid over-hype and exact estimates missing - need to be generated. </li></ul>BIOTECHNOLOGY DIVISION
  13. 13. Measuring the Biobased Economy <ul><li>Country strategies : visions, roadmaps, foresight. Goal setting </li></ul><ul><li>Measuring activity : eg investment, jobs, numbers of firms, churning, patents. Definitions, methodology and comparability. </li></ul><ul><li>Measuring impact : productivity, sustainability, demand and acceptability. Small impacts so far, pervasive sector. </li></ul><ul><li>Measuring cause and effect : Activity or Policy? Do we need to know . </li></ul>BIOTECHNOLOGY DIVISION
  14. 14. Inputs & Outputs BIOTECHNOLOGY DIVISION Alliances Patents as % GDP Employment VC investments Value No. firms Activities Sales Outputs R&D spend Inputs METRIC STAGE METRIC STAGE
  15. 15. Biotechnology R&D Total expenditure on biotechnology R&D by biotechnology-active firms, Million PPP$, 2003 BIOTECHNOLOGY DIVISION
  16. 16. Biotechnology firms Number of biotechnology firms, 2003 BIOTECHNOLOGY DIVISION
  17. 17. Biotechnology employment Biotechnology R&D employees, headcounts 2003 BIOTECHNOLOGY DIVISION
  18. 18. Biotechnology Patents BIOTECHNOLOGY DIVISION
  19. 19. Sales of Biotechnology firms, Million PPP$. 2003 BIOTECHNOLOGY DIVISION
  20. 20. Total venture capital investments in biotechnology, 2001 to 2003 combined BIOTECHNOLOGY DIVISION
  21. 21. Biotechnology venture capital Biotechnology venture capital investments as a percentage of GDP, 2003 BIOTECHNOLOGY DIVISION
  22. 22. Number of biotechnology alliances, 1990 to 2003 BIOTECHNOLOGY DIVISION
  23. 23. Where are we? <ul><li>Great on visioning . Real signs of success in raising interest/ investment. </li></ul><ul><li>Good measures of input – at national/ regional level. Still limited at sector/ firm level. </li></ul><ul><li>Progress on measuring activity , but needs to distinguish sectors and look at firm level. </li></ul><ul><li>Output measures lagging . Market sluggish and probably inefficient, basically no idea at national/ regional level. Firm level based on market response. </li></ul>BIOTECHNOLOGY DIVISION
  24. 24. What’s Missing? Would Resources Better be Put Elsewhere? <ul><li>Indicators (then measures) for productivity and other economic activity . </li></ul><ul><li>Indicators (then measures) for policy goals (health, sustainability). </li></ul><ul><li>Measures of value and value added (intangible assets). </li></ul><ul><li>Endogenous growth models? </li></ul>BIOTECHNOLOGY DIVISION
  25. 25. Realising a Bioeconomy “ an economy which captures the latent value in biological processes and renewable bioresources to produce improved health and sustainable growth and development ”. <ul><li>Building visions for the development of the bioeconomy </li></ul><ul><li>Identifying technical, financial, human capital, regulatory bottlenecks </li></ul><ul><li>Providing as much as possible a quantifiable benefit analysis of the main segments </li></ul><ul><li>Providing a road map of necessary policy choices ahead </li></ul>IBIOTECHNOLOGY DIVISION